Trump Signs Psychedelics Executive Order, FDA Clears First U.S. Ibogaine-Derivative Trial

On April 18, 2026, President Trump signed an executive order directing federal agencies to accelerate research and access pathways for psychedelic drugs, naming ibogaine explicitly. Days later, the FDA announced it had cleared the first-ever U.S. clinical study of an ibogaine derivative — a milestone that had eluded researchers for decades.

The Executive Order: What It Does and Doesn't Do

On April 18, 2026, President Trump signed an executive order which he stated would "dramatically accelerate access to new medical research and treatments based on psychedelic drugs." The FDA and DEA are directed to establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the Right to Try Act, including any necessary Schedule I handling authorizations for treating physicians and researchers. However, legal experts flagged a tension: referencing ibogaine directly in the Right to Try provision is unexpected because, of all the psychedelics, ibogaine is one that has arguably not met the basic safety requirements necessary for eligibility under the federal Right to Try Act — that statute requires completion of Phase I clinical trials, but the FDA has resisted ibogaine research partly due to concerns about heart-related risks. The order also does not change ibogaine's Schedule I status. Ibogaine remains a Schedule I controlled substance in the United States as of April 2026; the executive order directs federal agencies to study the compound and explore access pathways but does not change its legal status.

FDA Action: First U.S. Ibogaine-Derivative Trial Cleared

The FDA is allowing an early phase clinical study of noribogaine hydrochloride to move forward following an Investigational New Drug (IND) submission; the sponsor is investigating noribogaine as a potential treatment for alcohol use disorder, and this is the first instance in which the FDA has allowed a clinical study in the U.S. of a derivative of ibogaine. This decision allows the company developing the novel drug, DemeRx NB, to begin a Phase I clinical study in a closely monitored clinical setting in the United States — and it does not mean the drug has been approved or found to be safe or effective. DemeRx's drug is a metabolite of ibogaine, and the company says it doesn't carry the same risks as the original drug. Separately, the order requires the Secretary of HHS to allocate $50 million through the ARPA-H program to match investments made by state governments to advance research into psychedelic programs for populations with serious mental illness.

Texas IMPACT Program: Funding Secured, Legal Hurdle Remains

The statewide partnership — Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT) — will be led by UTHealth Houston and UTMB Health, and includes a broad consortium of leading Texas institutions including Texas Tech University, The University of Texas at Austin, Texas A&M University, Baylor College of Medicine, and JPS Health Network in Dallas. However, the path to releasing funds hit a snag. HHSC selected UTHealth Houston as the lead institution, but recent plans submitted to HHSC do not meet the requirements of Chapter 491 of the Health and Safety Code, including those related to matching state funds and allocation of revenue attributable to intellectual property and other rights. Texas is launching its own research program after state officials couldn't find a company to help develop ibogaine into a drug for FDA approval. Drug policy analysts noted that Texas lawmakers set the bar too high — to even be eligible for the $50 million state investment, companies had to provide a plan to get FDA approval, create a corporate presence in Texas, match the $50 million, and commit to Texas 20% of revenue from future sales of the drug.

Cardiac Safety: A Persistent and Serious Concern

Expanded political attention has not reduced ibogaine's documented cardiac risks. Ibogaine presents a clinically significant cardiac risk: it can prolong the QTc interval and trigger potentially fatal ventricular arrhythmias, including Torsades de Pointes. The mechanism involves ibogaine and noribogaine blocking hERG potassium channels in heart muscle cells, which delays repolarization — and critically, noribogaine persists in circulation well after the psychoactive experience ends, meaning the cardiac risk window extends beyond the acute session. A January 2026 review in Addiction found that QTc prolongation and arrhythmias occur even in patients without pre-existing cardiac conditions; most documented fatalities occurred in unsupervised settings, at supra-therapeutic doses, with concurrent use of QT-prolonging drugs or substances, or in people with undiagnosed cardiovascular disease. A February 2026 scoping review in Molecules noted that these cases frequently involved confounding factors such as pre-existing cardiac or hepatic disease, electrolyte disturbances, and polysubstance use — and consequently, although temporal associations between ibogaine exposure and death are consistently reported, causality cannot be unequivocally established based on the available data.

Recent Science: Neuroimaging and Transdiagnostic Hypotheses

A follow-up neuroimaging study published in iScience in February 2026 found increased cortical thickness in 11 brain regions, subcortical volumetric expansion in 8 regions, and an average reduction in predicted brain age of approximately 1.3 years at one month post-treatment. Researchers and the study authors themselves cautioned that both studies are observational with no placebo control arm, the sample is exclusively male highly selected Special Forces veterans treated at a private clinic in Mexico, and the authors themselves called for controlled clinical trials — these studies represent promising preliminary data, not proof of efficacy. A separate narrative review published in Frontiers in Pharmacology advanced the hypothesis that ibogaine's modulation of dopaminergic, glutamatergic, and neurotrophic pathways enables recalibration of mesocorticolimbic circuitry, representing a shared mechanism relevant across addiction, PTSD, OCD, and eating disorders.

Sources listed below. Verify with your medical provider.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals.